GB0328900D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0328900D0
GB0328900D0 GBGB0328900.6A GB0328900A GB0328900D0 GB 0328900 D0 GB0328900 D0 GB 0328900D0 GB 0328900 A GB0328900 A GB 0328900A GB 0328900 D0 GB0328900 D0 GB 0328900D0
Authority
GB
United Kingdom
Prior art keywords
beta
novel compounds
amyloid
memapsin
asp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0328900.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0328900.6A priority Critical patent/GB0328900D0/en
Publication of GB0328900D0 publication Critical patent/GB0328900D0/en
Priority to EP04803724A priority patent/EP1692143B1/en
Priority to PCT/EP2004/014076 priority patent/WO2005058915A1/en
Priority to KR1020067011376A priority patent/KR20060121164A/ko
Priority to AU2004299231A priority patent/AU2004299231A1/en
Priority to AT04803724T priority patent/ATE414090T1/de
Priority to BRPI0417476-3A priority patent/BRPI0417476A/pt
Priority to DE602004017777T priority patent/DE602004017777D1/de
Priority to RU2006124863/04A priority patent/RU2006124863A/ru
Priority to CA002549072A priority patent/CA2549072A1/en
Priority to CNA2004800416435A priority patent/CN1914214A/zh
Priority to JP2006543488A priority patent/JP2007513913A/ja
Priority to US10/596,296 priority patent/US20070073060A1/en
Priority to IL175819A priority patent/IL175819A0/en
Priority to IS8521A priority patent/IS8521A/xx
Priority to MA29143A priority patent/MA28241A1/fr
Priority to NO20063137A priority patent/NO20063137L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0328900.6A 2003-12-12 2003-12-12 Novel compounds Ceased GB0328900D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds
US10/596,296 US20070073060A1 (en) 2003-12-12 2004-12-09 Tricycle indole hydroxyethlamine derivatives and their use in the treatment of alzheimer's disease
RU2006124863/04A RU2006124863A (ru) 2003-12-12 2004-12-09 Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера
CNA2004800416435A CN1914214A (zh) 2003-12-12 2004-12-09 三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途
KR1020067011376A KR20060121164A (ko) 2003-12-12 2004-12-09 트리시클릭 인돌 히드록시에틸아민 유도체 및알쯔하이머병의 치료에서의 그의 용도
AU2004299231A AU2004299231A1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of Alzheimer's disease
AT04803724T ATE414090T1 (de) 2003-12-12 2004-12-09 Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
BRPI0417476-3A BRPI0417476A (pt) 2003-12-12 2004-12-09 derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer
DE602004017777T DE602004017777D1 (de) 2003-12-12 2004-12-09 Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
EP04803724A EP1692143B1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
CA002549072A CA2549072A1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
PCT/EP2004/014076 WO2005058915A1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
JP2006543488A JP2007513913A (ja) 2003-12-12 2004-12-09 三環式インドールヒドロキシエチルアミン誘導体およびアルツハイマー病の治療におけるそれらの使用
IL175819A IL175819A0 (en) 2003-12-12 2006-05-22 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
IS8521A IS8521A (is) 2003-12-12 2006-06-26 Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi
MA29143A MA28241A1 (fr) 2003-12-12 2006-06-26 Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
NO20063137A NO20063137L (no) 2003-12-12 2006-07-06 Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds

Publications (1)

Publication Number Publication Date
GB0328900D0 true GB0328900D0 (en) 2004-01-14

Family

ID=30130158

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0328900.6A Ceased GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds

Country Status (17)

Country Link
US (1) US20070073060A1 (https=)
EP (1) EP1692143B1 (https=)
JP (1) JP2007513913A (https=)
KR (1) KR20060121164A (https=)
CN (1) CN1914214A (https=)
AT (1) ATE414090T1 (https=)
AU (1) AU2004299231A1 (https=)
BR (1) BRPI0417476A (https=)
CA (1) CA2549072A1 (https=)
DE (1) DE602004017777D1 (https=)
GB (1) GB0328900D0 (https=)
IL (1) IL175819A0 (https=)
IS (1) IS8521A (https=)
MA (1) MA28241A1 (https=)
NO (1) NO20063137L (https=)
RU (1) RU2006124863A (https=)
WO (1) WO2005058915A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
EP1773756A2 (en) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
PT2185561E (pt) * 2007-07-27 2011-09-07 Sanofi Aventis Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
EP2310019A4 (en) * 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN104768949A (zh) * 2012-08-24 2015-07-08 特温蒂斯公司 苯并呋咱抗淀粉样蛋白化合物和方法
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease
WO2019075358A1 (en) * 2017-10-13 2019-04-18 Ghosh Arun K BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280096A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
IL175819A0 (en) 2006-10-05
KR20060121164A (ko) 2006-11-28
BRPI0417476A (pt) 2007-05-08
AU2004299231A1 (en) 2005-06-30
EP1692143A1 (en) 2006-08-23
IS8521A (is) 2006-06-26
DE602004017777D1 (de) 2008-12-24
CA2549072A1 (en) 2005-06-30
EP1692143B1 (en) 2008-11-12
NO20063137L (no) 2006-08-31
RU2006124863A (ru) 2008-01-20
WO2005058915A1 (en) 2005-06-30
ATE414090T1 (de) 2008-11-15
US20070073060A1 (en) 2007-03-29
CN1914214A (zh) 2007-02-14
JP2007513913A (ja) 2007-05-31
MA28241A1 (fr) 2006-10-02

Similar Documents

Publication Publication Date Title
GB0228410D0 (en) Novel Compounds
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
GB0328900D0 (en) Novel compounds
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
SI1776349T1 (sl) 2-amino-kinazolinski derivati, uporabni kot zaviralci beta-sekretaze (bace)
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
SI1789398T1 (sl) 2-amino-kinazolinski derivati, uporabni kot inhibitorji b-sekretaze (bace)
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
IL165996A0 (en) Novel thiophene acyl hydrazino derivatives method for preparing same use thereof as medicines pharmaceutical compositions and novel use
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)